Therapeutics News and Research

RSS

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

29 Jan 2013

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.2 million from the U.S. National Institute of General Medical Sciences of the National Institutes of Health to identify, test and develop a series of drug candidates for a number of diseases, including rheumatoid arthritis, heart disease and several neurodegenerative disorders.

28 Jan 2013

Tailored treatments and PSA screenings required to improve health outcomes in Ghana

Infectious diseases in Ghana tend to capture the most attention, but a quiet crisis may soon take over as the country's most threatening epidemic: cancer.

25 Jan 2013

Neuromuscular blockade (NMB) reversal

General anesthesia is made up of three components: hypnotic medicines, to induce sleep; analgesics, or medicines to inhibit pain; and NMB agents that induce muscle relaxation. Anesthesiology professionals use NMB to relax a patient’s muscles and prevent involuntary movement that could impact surgery.

24 Jan 2013

Clinical trial to evaluate cyclodextrin against Niemann-Pick disease type C1

A clinical trial to evaluate a drug candidate called cyclodextrin as a possible treatment for Niemann-Pick disease type C1 (NPC), a rare and fatal genetic disease, will start today, researchers announced.

24 Jan 2013

Researchers discover unique hairpin-like structure that facilitates Abeta clumping

Alzheimer's disease is the most common cause of late-life dementia. The disorder is thought to be caused by a protein known as the amyloid-beta protein, or Abeta, which clumps together in the brain, forming plaques that are thought to destroy neurons. This destruction starts early, too, and can presage clinical signs of the disease by up to 20 years.

24 Jan 2013

Institute of Bioengineering and Nanotechnology, IBM reveal new antimicrobial hydrogel

Researchers from IBM and the Institute of Bioengineering and Nanotechnology revealed today an antimicrobial hydrogel that can break through diseased biofilms and completely eradicate drug-resistant bacteria upon contact.

24 Jan 2013

KLF6-SV1 gene variant drives the spread of breast cancer

A team of researchers led by Goutham Narla, MD, PhD, at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, and collaborators at the Mount Sinai School of Medicine and Erasmus Medical Center, have discovered a gene variant that drives the spread of breast cancer.

23 Jan 2013

New apatamer can boost therapeutic effect of cell-based vaccines

A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

23 Jan 2013

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease.

23 Jan 2013

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

23 Jan 2013

New DNA chip could improve diagnosis and therapeutics of ADHD

Attention Deficit Hyperactivity Disorder (ADHD) is the most common childhood neuropsychiatric disorder. Yet there is currently no tool that will confirm the diagnosis of ADHD. In her thesis entitled "Development of a genotyping system to be applied in Attention Deficit Hyperactivity Disorder and its Pharmacogenetics".

22 Jan 2013

Cancer Targets & Therapeutics Conference to take place from Feb. 25-26 in Las Vegas

With the rapid progression of molecular biology and genetics, and the subsequent emergence of many new targets, emerging targets & therapeutics provides new opportunities for the prevention and treatment of several major disease systems.

19 Jan 2013

Penn Medicine to establish new center for treatment and research of blood diseases

Penn Medicine will establish the Philadelphia region's first dedicated center for the treatment and research of blood diseases by combining the expertise of physicians who specialize in the care of blood disorder patients of all ages along with basic science and clinical researchers who are working to advance treatments for these illnesses.

18 Jan 2013

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive - and thus vulnerable - to a novel cancer stem cell-targeting drug currently under development.

18 Jan 2013

AeriSeal System may provide relief for patients with emphysema

Those who have emphysema may soon be able to breathe a sigh of relief. That's because alternative ways to treat advanced cases of the condition are being developed.

17 Jan 2013

‘PapGene’ test detects endometrial and ovarian cancers

Researchers have adapted the papanicolaou smear test currently used to detect cervical cancer so that it can be used to screen women for endometrial and ovarian cancers.

14 Jan 2013

Johns Hopkins develops PapGene test to diagnose ovarian and endometrial cancers

Using cervical fluid obtained during routine Pap tests, scientists at the Johns Hopkins Kimmel Cancer Center have developed a test to detect ovarian and endometrial cancers. In a pilot study, the "PapGene" test, which relies on genomic sequencing of cancer-specific mutations, accurately detected all 24 (100 percent) endometrial cancers and nine of 22 (41 percent) ovarian cancers. Results of the experiments are published in the Jan. 9 issue of the journal Science Translational Medicine.

11 Jan 2013

Simple and inexpensive method to cut DNA could transform genetic medicine

A simple, precise and inexpensive method for cutting DNA to insert genes into human cells could transform genetic medicine, making routine what now are expensive, complicated and rare procedures for replacing defective genes in order to fix genetic disease or even cure AIDS.

10 Jan 2013

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.

9 Jan 2013

Therapeutics News and Research

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Tailored treatments and PSA screenings required to improve health outcomes in Ghana

Neuromuscular blockade (NMB) reversal

Clinical trial to evaluate cyclodextrin against Niemann-Pick disease type C1

Researchers discover unique hairpin-like structure that facilitates Abeta clumping

Institute of Bioengineering and Nanotechnology, IBM reveal new antimicrobial hydrogel

KLF6-SV1 gene variant drives the spread of breast cancer

New apatamer can boost therapeutic effect of cell-based vaccines

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

New DNA chip could improve diagnosis and therapeutics of ADHD

Cancer Targets & Therapeutics Conference to take place from Feb. 25-26 in Las Vegas

Penn Medicine to establish new center for treatment and research of blood diseases

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

AeriSeal System may provide relief for patients with emphysema

‘PapGene’ test detects endometrial and ovarian cancers

Johns Hopkins develops PapGene test to diagnose ovarian and endometrial cancers

Simple and inexpensive method to cut DNA could transform genetic medicine

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News